Table 6 The predicted biological effect by the four shortlisted compounds using PASSOnline webserver at Pa > Pi.
From: Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer
Predicted biological activities | Pa | Pi |
---|---|---|
Valganciclovir | ||
 Immunostimulant | 0.9 | 0.004 |
 Aldehyde oxidase substrate | 0.872 | 0.002 |
 Antiviral (Herpes) | 0.861 | 0.002 |
 Antiviral | 0.809 | 0.004 |
 DNA-directed DNA polymerase inhibitor | 0.785 | 0.003 |
 Radiosensitizer | 0.77 | 0.004 |
 Antiinfective | 0.77 | 0.005 |
 Cytostatic | 0.763 | 0.008 |
 Immunomodulator | 0.749 | 0.003 |
 Antiviral (CMV) | 0.698 | 0.001 |
 Antiviral (Poxvirus) | 0.662 | 0.011 |
 ADP-thymidine kinase inhibitor | 0.664 | 0.017 |
 Antineoplastic antimetabolite | 0.652 | 0.005 |
 Fibroblast growth factor agonist | 0.651 | 0.012 |
 Macrophage stimulant | 0.639 | 0.005 |
 Immunosuppressant | 0.641 | 0.024 |
 Chemosensitizer | 0.591 | 0.007 |
 Undecaprenyl-phosphate mannosyltransferase inhibitor | 0.593 | 0.011 |
 DNA synthesis inhibitor | 0.589 | 0.011 |
 Peptide agonist | 0.601 | 0.028 |
 DNA polymerase I inhibitor | 0.557 | 0.005 |
 Mannotetraose 2-alpha-N-acetylglucosaminyltransferase inhibitor | 0.594 | 0.045 |
 Thiol oxidase inhibitor | 0.555 | 0.016 |
 Xanthine oxidase substrate | 0.528 | 0.002 |
 Anticarcinogenic | 0.509 | 0.018 |
 Dasatinib | ||
 Tyrosine kinase inhibitor | 0.825 | 0.004 |
 Lck kinase inhibitor | 0.802 | 0.002 |
 Src kinase inhibitor | 0.794 | 0.003 |
 Protein kinase inhibitor | 0.713 | 0.007 |
 Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.694 | 0.003 |
 Proto-oncogene tyrosine-protein kinase Fgr inhibitor | 0.687 | 0.002 |
 T cell inhibitor | 0.604 | 0.003 |
 Signal transduction pathways inhibitor | 0.569 | 0.022 |
 Protein-tyrosine kinase Lyn inhibitor | 0.53 | 0.002 |
 Immunosuppressant | 0.555 | 0.034 |
 Growth factor agonist | 0.511 | 0.004 |
 Protein-tyrosine kinase p55(blk) inhibitor | 0.506 | 0.003 |
 Anaphylatoxin receptor antagonist | 0.55 | 0.05 |
Indacaterol | ||
 Adrenergic | 0.813 | 0.003 |
 Chronic obstructive pulmonary disease treatment | 0.717 | 0.004 |
 Bronchodilator | 0.661 | 0.003 |
 Antiasthmatic | 0.667 | 0.01 |
 Adrenaline agonist | 0.655 | 0.002 |
 Proteasome ATPase inhibitor | 0.662 | 0.02 |
 Muramoyltetrapeptide carboxypeptidase inhibitor | 0.642 | 0.02 |
 Glyceryl-ether monooxygenase inhibitor | 0.558 | 0.039 |
 Beta adrenoreceptor agonist | 0.479 | 0.002 |
 Spasmolytic | 0.488 | 0.03 |
 Uterine relaxant | 0.462 | 0.007 |
 Mycothiol-S-conjugate amidase inhibitor | 0.449 | 0.034 |
 HERG 1 channel blocker | 0.448 | 0.035 |
 UGT2B12 substrate | 0.441 | 0.034 |
 Mannotetraose 2-alpha-N-acetylglucosaminyltransferase inhibitor | 0.479 | 0.076 |
 Beta 1 adrenoreceptor agonist | 0.395 | 0.003 |
 Antidiabetic | 0.387 | 0.047 |
 Skeletal muscle relaxant | 0.363 | 0.04 |
 CYP2J2 substrate | 0.451 | 0.13 |
 Antineoplastic alkaloid | 0.342 | 0.025 |
Novobiocin | ||
 Antimycobacterial | 0.77 | 0.004 |
 Antibacterial | 0.69 | 0.005 |
 Antineoplastic | 0.69 | 0.028 |
 Lactase inhibitor | 0.629 | 0.01 |
 DNA gyrase inhibitor | 0.524 | 0.001 |
 HIF1A expression inhibitor | 0.562 | 0.04 |
 Anticarcinogenic | 0.526 | 0.017 |
 CYP2H substrate | 0.567 | 0.083 |